Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam
mBio · 19.12.2023 · 14 (6)
DOI: 10.1128/mbio.01118-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 19.12.2023. Verfasst von Andrea M Hujer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Research Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Anti-Bacterial Agents, Azabicyclo Compounds, Cyclooctanes. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multi-drug resistant (MDR) Pseudomonas aeruginosa harbor a complex array of β-lactamases and non-enzymatic resistance mechanisms. In this study, the activity of a β-lactam/β-lactam-enhancer, cefepime/zidebactam, and novel β-lactam/β-lactamase inhibitor combinations was determined against an MDR phenotype-enriched, challenge panel of P. aeruginosa ( n = 108). Isolates were multi-clonal as they belonged to at least 29 distinct sequence types (STs) and harbored metallo-β-lactamases, serine β-lactamases, penicillin binding protein (PBP) mutations, and other non-enzymatic resistance mechanisms. Ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, and cefepime/taniborbactam demonstrated MIC 90 s of >128 mg/L, while cefepime/zidebactam MIC 90 was 16 mg/L. In a neutropenic-murine lung infection model, a cefepime/zidebactam human epithelial-lining fluid-simulated regimen achieved or exceeded a translational end point of 1−log 10 kill for the isolates with elevated cefepime/zidebactam MICs (16–32 mg/L), harboring VIM-2 or KPC-2 and alterations in PBP2 and PBP3. In the same model, to assess the impact of zidebactam on the pharmacodynamic (PD) requirement of cefepime, dose-fractionation studies were undertaken employing cefepime-susceptible P. aeruginosa isolates. Administered alone, cefepime required 47%–68% f T >MIC for stasis to ~1 log 10 kill effect, while cefepime in the presence of zidebactam required just 8%–16% for >2 log 10 kill effect, thus, providing the pharmacokinetic/PD basis for in vivo efficacy of cefepime/zidebactam against isolates with MICs up to 32 mg/L. Unlike β-lactam/β-lactamase inhibitors, β-lactam enhancer mechanism-based cefepime/zidebactam shows a potential to transcend the challenge of ever-evolving resistance mechanisms by targeting multiple PBPs and overcoming diverse β-lactamases including carbapenemases in P. aeruginosa . IMPORTANCE Compared to other genera of Gram-negative pathogens, Pseudomonas is adept in acquiring complex non-enzymatic and enzymatic resistance mechanisms thus remaining a challenge to even novel antibiotics including recently developed β-lactam and β-lactamase inhibitor combinations. This study shows that the novel β-lactam enhancer approach enables cefepime/zidebactam to overcome both non-enzymatic and enzymatic resistance mechanisms associated with a challenging panel of P. aeruginosa . This study highlights that the β-lactam enhancer mechanism is a promising alternative to the conventional β-lactam/β-lactamase inhibitor approach in combating ever-evolving MDR P. aeruginosa .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
- Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India.
- Wockhardt Research Centre, Aurangabad, Maharashtra, India.
- Departments of Pharmacology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, and the CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA…
ORCID-Profile: Andrea M Hujer, Steven H Marshall, Andrew R Mack, Prashant R Joshi, Balaji Veeraraghavan, Robert A Bonomo
Zitieren
APA
Hujer, A. M., Marshall, S. H., Mack, A. R., Hujer, K. M., Bakthavatchalam, Y. D., Umarkar, K., Palwe, S. R., Takalkar, S., Joshi, P. R., Shrivastava, R., Periasamy, H., Bhagwat, S. S., Patel, M. V., Veeraraghavan, B., & Bonomo, R. A. (2023). Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam. mBio, 14(6). https://doi.org/10.1128/mbio.01118-23
Vancouver
Hujer AM, Marshall SH, Mack AR, Hujer KM, Bakthavatchalam YD, Umarkar K, et al. Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam. mBio. 2023;14(6). doi:10.1128/mbio.01118-23
BibTeX
@article{Hujer2023,
author = {Hujer, Andrea M and Marshall, Steven H and Mack, Andrew R and Hujer, Kristine M and Bakthavatchalam, Yamuna Devi and Umarkar, Kushal and Palwe, Snehal R and Takalkar, Swapna and Joshi, Prashant R and Shrivastava, Rahul and Periasamy, Hariharan and Bhagwat, Sachin S and Patel, Mahesh V and Veeraraghavan, Balaji and Bonomo, Robert A},
title = {Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam},
journal = {mBio},
year = {2023},
volume = {14},
number = {6},
doi = {10.1128/mbio.01118-23}
}
EUVIMED